Kronos Worldwide, Inc. filings document operating results, governance, capital structure and material events for a titanium dioxide producer with common stock listed on the New York Stock Exchange under KRO. Recent Form 8-K reports furnish earnings releases, dividend announcements, executive succession disclosures and Regulation FD information.
The filing record also includes definitive proxy materials for annual meeting matters and board governance, as well as debt financing disclosures involving Kronos International, Inc., a wholly owned subsidiary, and senior secured notes due 2029. These documents describe registered securities, subsidiary obligations, indenture supplements, material agreements and executive compensation matters.
Kramer Kevin B reported acquisition or exercise transactions in this Form 4 filing.
Kronos Worldwide Inc reported that director Kevin B. Kramer received a grant of 5,550 shares of common stock at a reference value of $7.22 per share. According to the footnote, the shares were issued for no cash consideration under the company’s 2012 Director Stock Plan, reflecting equity-based board compensation rather than an open-market purchase. After this award, Kramer directly holds 29,810.461 shares of Kronos Worldwide common stock.
KRONOS WORLDWIDE INC director John E. Harper received a grant of 5,550 shares of common stock, valued at $7.22 per share. These shares were issued for no cash consideration under the Kronos Worldwide, Inc. 2012 Director Stock Plan, reflecting equity-based compensation rather than an open-market purchase.
Following this award, Harper directly holds 21,800 shares of Kronos Worldwide common stock. The transaction is classified as a grant or award acquisition, indicating routine director compensation aligned with the company’s stock-based incentive program.
Feehan Loretta J. reported acquisition or exercise transactions in this Form 4 filing.
KRONOS WORLDWIDE INC director Loretta J. Feehan reported receiving a stock award of 5,550 shares of common stock on May 13, 2026. The shares were issued at a reference value of $7.22 per share for no cash consideration under the Kronos Worldwide, Inc. 2012 Director Stock Plan. Following this grant, she directly holds 26,800 common shares.
Kronos Worldwide director Dr. R. Gerald Turner received a stock award. On May 13, 2026, he acquired 5,550 shares of Kronos Worldwide common stock at a grant value of $7.22 per share.
The shares were issued for no cash consideration under the Kronos Worldwide, Inc. 2012 Director Stock Plan as part of his board compensation. Following this grant, Dr. Turner directly holds 37,595.618 shares of the company’s common stock.
Kronos Worldwide, Inc. reported the results of its 2026 annual stockholder meeting and announced a regular cash dividend. Stockholders representing 93.2% of the 115,053,116 shares eligible to vote participated. All eight director nominees were elected, each receiving support from at least 85.6% of the shares eligible to vote.
Stockholders also approved, on a nonbinding advisory basis, the compensation of the company’s named executive officers with 86.3% of eligible shares in favor. The board declared a quarterly dividend of $0.05 per share, payable on June 18, 2026, to stockholders of record at the close of business on June 4, 2026.
Kronos Worldwide, Inc. reported a first quarter 2026 net loss of $4.8 million, or $0.04 per share, reversing net income of $18.1 million, or $0.16 per share, a year earlier. Net sales rose to $509.8 million from $489.8 million, a 4% increase driven mainly by higher TiO₂ sales volumes in North America, Latin America and export markets and favorable currency movements, partially offset by lower prices and weaker European volumes.
Income from operations fell to $12.6 million from $38.4 million as lower average TiO₂ selling prices and reduced production volumes outweighed higher volumes and lower production costs from 2025 cost reduction initiatives and lower raw material and energy costs. TiO₂ segment profit declined to $15.1 million from $41.6 million, and EBITDA dropped to $27.7 million from $51.2 million. Management highlighted a $74.5 million sequential improvement in segment profit versus the fourth quarter of 2025 after restructuring actions, while noting a $2.0 million tax expense related to an uncertain German tax position.
Kronos Worldwide, Inc. reported a small net loss in the first quarter of 2026 as softer pricing outweighed higher volumes and cost savings. Net sales rose to $509.8 million from $489.8 million, driven by a 4% increase in TiO₂ sales volumes and favorable currency movements, partly offset by a 6% decline in average TiO₂ selling prices.
Gross margin narrowed to 16% of sales from 22% as lower prices and higher reported cost of sales more than offset lower production costs and reduced unabsorbed fixed costs. The company posted a net loss of $4.8 million, or $(0.04) per share, versus net income of $18.1 million, or $0.16 per share, a year earlier, including $2.0 million of income tax expense for an uncertain German tax position. Operating cash outflow improved to $51.3 million from $102.4 million as inventories declined, while long-term debt increased to $602.7 million, supported by Global Revolver availability of about $287 million.
Kronos Worldwide, Inc. is calling its 2026 annual stockholder meeting for May 13, 2026 in Dallas to elect eight directors and hold a nonbinding Say‑on‑Pay vote on executive compensation. Only holders of common stock at the March 17, 2026 record date may vote, with 115,053,116 shares outstanding.
Valhi and NLKW together own about 81.0% of the common stock and have indicated they will vote for all director nominees and for Say‑on‑Pay, effectively determining the outcomes and ensuring a quorum. Kronos is a NYSE “controlled company” and uses that status to forgo a separate nominating committee.
Executive officers, including CEO Brian W. Christian, are employed by Contran and provided under an intercorporate services agreement. In 2025 Kronos paid Contran about $25.8 million for these shared services, and the listed executive “salary” amounts (for example, $2,293,000 for former CEO James M. Buch in 2025) reflect Kronos’ allocated portion of Contran’s costs rather than direct payroll. Named executives receive no stock options or other equity awards, and there were no plan-based grants or option exercises in 2025. Non‑employee directors are paid cash retainers plus an annual stock grant worth about $20,000 and must maintain shareholdings equal to at least three times the base cash retainer.
Kronos Worldwide, Inc. reported a much deeper net loss of $82.8 million, or $.72 per share, in Q4 2025, versus a net loss of $13.2 million, or $.12 per share, in Q4 2024, as higher costs outweighed largely flat sales.
For full-year 2025, the company posted a net loss of $110.9 million, or $.96 per share, compared with net income of $86.2 million, or $.75 per share, in 2024. Net sales slipped 1% to $1.86 billion as higher TiO2 volumes could not offset lower selling prices.
Profitability weakened mainly due to about $111 million of unabsorbed fixed production costs from curtailments, lower average TiO2 prices, higher distribution and warehousing costs, workforce reduction charges of $10.3 million, a $9.0 million U.S. pension plan settlement loss, and non-cash German deferred tax expense of $19.3 million. EBITDA fell to $16.1 million in 2025 from $252.9 million in 2024, which had included a $64.5 million non-cash gain from the Louisiana Pigment Company acquisition.